Panel Discussion: With Unprecedented Phase III Progress & Expected Regulatory Feedback on Submissions, What Direction is Provided for the Dry AMD/GA Field?
Time: 4:45 pm
day: Day One
- How can drug developers cut to the real barriers, and debate what is truly required to break through to
successful treatments for dry-AMD?
- Discuss how slow disease progression and a less than ideal endpoint measurement method lead to
clinical trials that are necessarily large, lengthy and expensive
- Examine how innovations in clinical trials with novel endpoints, non-traditional study designs and the
use of surrogate diseases, developers can reduce the patient sample size and consequently lower the
budget of clinical trials